1992
DOI: 10.1097/00000421-199204000-00008
|View full text |Cite
|
Sign up to set email alerts
|

Phase II Trial of Indicine N-Oxide in Relapsed Acute Leukemia of Childhood

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

1997
1997
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…Regarding the plant families Asteraceae, Composites, or Leguminosae, many of their members produce pyrrolizidine alkaloids-potent cytotoxic, carcinogenic, and/or anti-carcinogenic compounds [84,85]-which probably act by crosslinking DNA [86]. One of these compounds, indicine N-oxide, advanced to clinical trial [87,88], but unremarkable Mans, da Rocha, Schwartsmann anti-tumor effects and unacceptably severe, irreversible hepatotoxicity led to the termination of its further development.…”
Section: Compound Acquisition Through Ecological Survey/rational Searchmentioning
confidence: 99%
“…Regarding the plant families Asteraceae, Composites, or Leguminosae, many of their members produce pyrrolizidine alkaloids-potent cytotoxic, carcinogenic, and/or anti-carcinogenic compounds [84,85]-which probably act by crosslinking DNA [86]. One of these compounds, indicine N-oxide, advanced to clinical trial [87,88], but unremarkable Mans, da Rocha, Schwartsmann anti-tumor effects and unacceptably severe, irreversible hepatotoxicity led to the termination of its further development.…”
Section: Compound Acquisition Through Ecological Survey/rational Searchmentioning
confidence: 99%
“…As indicine-N-oxide showed promising results as an anticancer agent in in vitro and in vivo assays, clinical trials were conducted for acute leukemia; however, due to severe hepatotoxicity, the compound was not further tested [113,114]. One clinical trial investigated the effect of indicine-N-oxide on patients with progressive acute leukemia refractory to standard chemotherapeutics.…”
Section: Anticancer Propertiesmentioning
confidence: 99%
“…Further, no clinically significant objective responses were noted in patients, thus disappointingly ceasing the scientific investigation into indicine N-oxide. Miser et al (155) carried out a phase II clinical trial in children with relapsed acute leukemia and although indicine N-oxide showed some anti-leukemic activity, it was associated with severe and irreversible hepatotoxicity. PA appears to be a compound of interest for anti-cancer therapy due to its cytotoxic and angiogenesis inhibiting property.…”
Section: Pas and Cancermentioning
confidence: 99%